TICKERNERD
Menu
HSICHSICHealthcare · Medical Distribution

HSIC Stock Forecast: Henry Schein, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$85
−0.24% on the day

The 17 Wall Street analysts covering Henry Schein, Inc. hold a median 12-month price target of $101 — +19.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 19 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$9.7B
Ticker Nerd rank
81 / 100
Median analyst target
$101
Analysts covering
17
Revenue$3.5B+6.7% y/y
Operating income$200.0M
Net income$102.0M
Free cash flow$196.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
−4.9%
YTD
+12.3%
1Y
+23.8%
From 52W high
−6.6%
From 52W low
+36.8%
$62
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HSIC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Henry Schein, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Momentum
85
Revisions
75
Value
72
Quality
68
Issuance
66
Growth
58
Accruals
50
Size
16

Volatility (97): The share price has been relatively steady.

Accruals (50): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HSIC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HSIC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26HSICHigh $112Median $101Low $64

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
9 Buy7 Hold1 Sell
Low $64Median $101High $112

The green dot is the last close — the median target sits +19.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Aug 2026BTIGMaintainsBuy$100 → $110
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$86 → $100
5 Aug 2026BTIGReiteratesBuy—
5 Aug 2026BTIGReiteratesBuy$100
5 Aug 2026CitigroupMaintainsBuy—
5 Aug 2026CitigroupMaintainsBuy$100 → $112
5 Aug 2026UBSMaintainsNeutral$89 → $94
5 Aug 2026UBSMaintainsNeutral—
29 July 2026Piper SandlerMaintainsOverweight$91 → $95
29 July 2026Piper SandlerMaintainsOverweight—
28 July 2026UBSMaintainsNeutral$85 → $89
28 July 2026UBSMaintainsNeutral—
9 July 2026BMO CapitalInitiatesMarket Perform—
11 June 2026BTIGUpgradeBuy—
6 May 2026MizuhoMaintainsNeutral—
6 May 2026UBSMaintainsNeutral—
24 Apr 2026Morgan StanleyMaintainsUnderweight—
16 Apr 2026BTIGInitiatesNeutral—
15 Apr 2026CitigroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HSIC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HSIC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Henry Schein, Inc. returned +23.8% against +16.3% for the S&P 500, dividends included.

HSIC vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26HSICS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HSIC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
14
Analysts cutting
1
Fundamentals

Henry Schein, Inc. (HSIC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.7×

Cheaper than 30% of US stocks

Price / sales
0.7×

Cheaper than 76% of US stocks

Price / book
3.0×

Cheaper than 32% of US stocks

EV / EBITDA
13.6×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
6.7%

Higher than 43% of US stocks

Earnings growth (YoY)
9.3%

Higher than 47% of US stocks

Gross margin
31.8%

Higher than 37% of US stocks

Operating margin
5.8%

Higher than 56% of US stocks

Net margin
3.0%

Higher than 55% of US stocks

Returns & dividend
Return on equity
8.9%

Higher than 61% of US stocks

Return on assets
4.4%

Higher than 73% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Henry Schein, Inc. (HSIC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Henry Schein, Inc. has a market value of $9.7B and an enterprise value of $14.7B.

  • Revenue in the twelve months to 30 June 2026: $13.6B. The latest quarter grew 6.7% year on year.

  • Net income over the same four quarters: $426.0M, a 3.1% net margin.

  • Diluted earnings per share, trailing twelve months: $3.43.

  • Free cash flow in the twelve months to 30 June 2026: $513.0M, after $56.0M of capital spending.

  • Henry Schein, Inc. spent $728.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 111.9M.

  • Trailing P/E: 24.7×; forward P/E: 14.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Henry Schein, Inc. employs 25,000 people — $544K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

HSIC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
HSICHenry Schein, Inc.$9.7B
81
CAHCardinal Health, Inc.$52.4B
96
CORCencora, Inc.$59.9B
70
MCKMcKesson Corp.$102.4B
86
PODDInsulet Corp.*$9.7B
89
KYMRKymera Therapeutics, Inc.*$9.8B
74
GKOSGlaukos Corp.*$9.7B
92

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Henry Schein, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HSIC news & analysis

Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Seeking Alpha · 19 Sept 2026positive

Henry Schein reported strong Q2 results with revenue up 6.7% to $3.46B, along with improved net income and cash flow and growth across all business segments. Management raised 2026 guidance to 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, with recent share price outperformance versus the S&P 500.

Why it matters — A Henry Schein watcher would care because the company reported broad segment growth, strong financial improvements, and raised its 2026 outlook, signaling continued operational momentum.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research published a piece asking whether investors are currently undervaluing Henry Schein (HSIC). The article explains Zacks' focus on its Rank system, which emphasizes earnings estimates and estimate revisions while also monitoring value, growth, and momentum trends.

Why it matters — A HSIC watcher would care because this analytical coverage highlights whether current market pricing aligns with the company's earnings-estimate and valuation signals.

What Makes Henry Schein (HSIC) a New Buy Stock

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research upgraded Henry Schein (HSIC) to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade may support the stock in the near term.

Why it matters — The upgrade signals increased analyst optimism about Henry Schein's earnings outlook, which HSIC watchers would find relevant when assessing near-term momentum.

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 16 Sept 2026neutral

Zacks Investment Research published a comparison of Henry Schein (HSIC) and Straumann Holding AG (SAUHY) as value investment options in the Medical - Dental Supplies sector. The article examines which of the two stocks offers better value for investors.

Why it matters — A HSIC watcher would care because the piece directly compares the company's value proposition against a key dental-supplies competitor.

Here's Why Henry Schein (HSIC) is a Strong Value Stock

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research published an article explaining why Henry Schein (HSIC) is considered a strong value stock, referencing the Zacks Style Scores premium research feature that helps investors identify strong stocks.

Why it matters — A HSIC watcher would care because the article highlights Henry Schein as a strong value stock, potentially drawing investor attention to the company.

FAQ

Frequently asked questions about HSIC stock

What is the HSIC stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Henry Schein, Inc. have a median 12-month price target of $101, with estimates ranging from $64 to $112. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HSIC stock a buy right now?

Of the 17 analysts covering Henry Schein, Inc., 9 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Henry Schein, Inc. 81 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HSIC?

As at 19 Sept 2026, Henry Schein, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will HSIC stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +19.0% from the last close, and Ticker Nerd's factor model ranks Henry Schein, Inc. 81 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HSIC stock forecast for 2030?

No analyst covering Henry Schein, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $64 to $112 over the next 12 months.

How has HSIC stock performed over the past year?

Henry Schein, Inc. returned +23.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Henry Schein, Inc. do?

Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals.

What is the latest news on HSIC?

The most recent item we track (Seeking Alpha, 19 Sept 2026): "Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher". Henry Schein reported strong Q2 results with revenue up 6.7% to $3.46B, along with improved net income and cash flow and growth across all business segments. Management raised 2026 guidance to 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, with recent share price outperformance versus the S&P 500.

Company

About Henry Schein, Inc.

Henry Schein, Inc. is a health care solutions company that serves office-based dental, medical, and veterinary professionals. Henry Schein provides a broad range of products and services through its core businesses in healthcare distribution, specialty products, and technology-enabled value-added services. Its offerings include consumable supplies, dental equipment, practice-management software, logistics support, and related clinical solutions that help practices manage daily operations more efficiently. The company also supports dental laboratories, government and institutional health care clinics, and other alternate care sites with products and services tailored to professional workflows. With a strong presence in dental and medical markets, Henry Schein plays an important role in the supply chain for outpatient health care providers and practice support services.

CEO Mr. Frederick M. Lowery · 25,000 employees · United States · https://www.henryschein.com